I think its a classic case of COVID insecurity risk-aversion, wouldn't be to worried about it.
I'm with Gus, biomed is a long hold. Day changes are good to keep up with but real SP changes will come with announcements and approvals. Patients is the name of the game here. While I'm a new PAB holder, I have some past experience with other bioemds and I waited really long for some price action, but once it's up and gaining momentum that sky is the limit
Ann: PAT-DX1 Improves Survival in Model of Pancreatic Cancer, page-34
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 154511 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 4813825 | 5 |
View Market Depth
| Last trade - 10.20am 31/07/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable